Sagimet Biosciences Inc. (SGMT) Current Ratio
- Current ratio · latest quarter: Value 45.02×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 45.02× | Current assets / current liabilities. $243.99M ÷ $5.42M ≈ 45.02× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 243.99M USD | Assets, Current |
| Current obligations | 5.42M USD | Liabilities, Current |
| Cash and equivalents | 165.90M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 74.23M USD | Marketable Securities, Current |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 1.13M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $243.99M | $5.42M | $165.90M | $74.23M | (m) | (m) | $1.13M | (m) | 45.02× |
| 2026-03-31 | $107.72M | $5.30M | $36.63M | $67.91M | (m) | (m) | $2.30M | (m) | 20.34× |
| 2025-12-31 | $116.40M | $5.10M | $35.02M | $78.10M | (m) | (m) | $1.31M | (m) | 22.82× |
| 2025-09-30 | $119.48M | $9.15M | $32.50M | $84.20M | (m) | (m) | $4.24M | (m) | 13.06× |
| 2025-06-30 | $127.20M | $7.25M | $42.33M | $83.08M | (m) | (m) | $1.92M | (m) | 17.55× |
| 2024-12-31 | $152.77M | $4.45M | $75.84M | $75.41M | (m) | (m) | $1.43M | (m) | 34.30× |
| 2023-12-31 | $96.65M | $5.65M | $75.14M | $19.76M | (m) | (m) | $186.00K | (m) | 17.09× |
| 2023-09-30 | $102.82M | $5.05M | $101.84M | $0.00 | (m) | (m) | $1.70M | (m) | 20.36× |
| 2023-06-30 | $21.35M | $5.29M | $18.51M | $0.00 | (m) | (m) | $2.72M | (m) | 4.04× |
| 2022-12-31 | $32.79M | $5.28M | $158.00K | $32.19M | (m) | (m) | $1.13M | (m) | 6.21× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |